Tata 1mg turns EBITDA positive across core units; diagnostics ARR crosses ₹600 cr
Tata 1mg hit EBITDA breakeven across ePharmacy, diagnostics and D2C in FY26. Diagnostics ARR crossed ₹600 cr (+40% YoY) across 19 NABL labs in 70 cities. Speciality pharma grew 65%, D2C ARR hit ₹200 cr. Offline footprint to scale from 280 to 500+ stores over the next 12 months.
Tata 1mg turned EBITDA positive across all core units in FY26, with diagnostics crossing ₹600 cr ARR and ePharmacy breaking even. Plans to expand offline retail from 280 to 500+ stores in 12 months.